logo
Family's plea after 2yo girl's tragic death

Family's plea after 2yo girl's tragic death

Yahoo29-07-2025
A Perth family has issued an emotional plea after their two-year-old daughter died from the flu.
In a letter shared by the Immunisation Foundation of Australia, the heartbroken family described how the health of their two-year-old daughter, Aabi, rapidly deteriorated from the virus.
Only a few months away from turning three, Aabi and her family had returned to their home in Perth on April 30 after spending a month abroad in India visiting relatives.
Aabi's parents said she was 'reluctant' to return to daycare, but was sent back the next day.
It was only a few days later that Aabi vomited after eating her regular banana and milk.
'I initially thought it was due to her energetic play with her sister,' her mother wrote.
'As I cleaned her, I noticed she felt lukewarm.'
The two-year-old complained of a headache, with her mother giving her a dose of paracetamol syrup and a 'gentle forehead massage' that seemed to help.
While Aabi's mood seemed to improve, her fever - and the niggling headache - returned a short time later.
'(On) Sunday, May 4th, she woke as usual - enjoying two biscuits with my tea, her milk, and then a banana,' her mother wrote.
'She was playing, singing, and seemed well.
'Relieved, I started my regular Sunday household tasks while the girls entertained themselves.'
However by about 11am that morning, Aabi's temperature was rising again and her headache had returned.
'I sat beside her, waiting for the fever to drop, but it kept climbing,' her mother wrote.
Aabi's fever kept climbing to 40.6C and she was rushed to hospital, where her dehydration made it difficult for doctors to figure out the problem.
'It felt like she deteriorated significantly and too quickly,' her mother said.
Aabi had a 'gentle seizure' while in hospital and was later diagnosed with influenza.
'The decision was made to perform a CT scan and then transfer her to the ICU, as she was highly febrile and partially unconscious,' the letter read.
However, the little girl's health had deteriorated too quickly for the CT scan to be effective and she instead required an MRI scan.
Aabi's mum said it was then she believed they had lost their little girl, saying her pupils were non-responsive and 'she was beyond anyone's help'.
In the span of a few days, Aabi had gone from being a 'healthy, happy, active, and fun-loving child' to lying unconscious in the hospital bed.
The MRI scan confirmed the worst.
'The MRI confirmed total brain death due to acute necrotising encephalitis, a devastating complication of the influenza infection,' her mother wrote.
'The virus's rapid progression with such minimal initial symptoms – just a normal fever and headache, which so many children her age experience regularly – gave us no indication of the extreme seriousness of the situation.'
Aabi's mother said doctors suspect her daughter's immune system reacted 'much more aggressively than usual', which led to 'acute inflammation and severe damage to her brain'.
'We lost our beautiful Aabi at the hands of what seemed like a 'mere virus',' she said.
'Aabi will forever be two years and nine months old,' her mother wrote, describing her daughter as the 'radiant joy of our lives and the very heart of our home'.
Flu spike 'really concerning'
Immunisation Foundation of Australia founder Catherine Hughes said Aabi's story was a reminder of the tragic impact influenza can have, and highlights just how vulnerable young children are to infectious diseases.
She said an ongoing spread of misinformation was leading to shockingly low rates of flu vaccination, something she described as a 'serious public health concern'.
According to figures from the National Centre for Immunisation Research and Surveillance (NCRIS), more than 230,000 lab-confirmed flu cases have been reported in the country as of late July.
Less than a quarter of those cases are children under the age of five.
Ms Hughes said the numbers were 'really concerning'.
'Many of us might mistakenly think of the flu as 'just a bad cold', especially after a mild case,' she told NewsWire.
'However, influenza can be extremely severe, leading to serious complications, hospitalisation, and death, even for healthy children and adults.'
This could be reduced with higher vaccination rates, she said.
'We urge families to prioritise vaccination as a proactive step to protect their children, prevent the wider spread of the virus, and ultimately, help protect all Australians,' she told NewsWire.
Monash University Epidemiological Modelling Unit for the School of Public Health and Preventive Medicine associate professor James Trauer reiterated it was important for Australians to get vaccinated against the flu.
He told NewsWire the flu vaccine presented 'little chemicals to the immune system' that are in both the vaccine and flu virus, meaning the body is exposed to the chemicals without the body having to be exposed to the flu virus itself.
'So you develop antibodies … once you've got those antibodies, you have a more effective, more rapid response to the vaccine,' he said.
He said children under five and the population over 65 were the biggest priority for flu vaccinations, though the general public - particularly those with young children - should also get the jab.
'The flu transmits a lot within family units,' he said.
'(The) flu causes a major epidemic every winter, and people do die of it every year, and so it's important for us to do everything that we can (to prevent it).'
While there are 'some other treatments' to prevent the virus, he said 'vaccination is really the best … preventive and effective intervention' that can 'really help us to reduce the flu each winter'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RSV symptoms as 'serious virus' coming to UK after Australia surge
RSV symptoms as 'serious virus' coming to UK after Australia surge

Yahoo

time44 minutes ago

  • Yahoo

RSV symptoms as 'serious virus' coming to UK after Australia surge

NHS experts have urged people who are eligible for a vaccine against respiratory syncytial virus (RSV) to take it up after cases surged in Australia. Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often provides a good indication of how viruses will spread in England. Since the start of 2025, the virus has been progressively spreading, with nearly half of reported cases occurring in children under five years old. Kate Brintworth, chief midwifery officer for NHS England, said: "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." READ MORE: Walker spots giant 'alien' jellyfish washed up on beach READ MORE: Warning over serious virus affecting newborns after surge in cases Dr Andy Whittamore, GP and clinical lead at Asthma + Lung UK, who has pointed out the key symptoms to watch out for and shared some strategies to help protect yourself and your family. What is RSV? He said: "Respiratory syncytial virus is a virus that causes symptoms very similar to the common cold, most of us get it at some point and don't even know that we've had it." According to Asthma + Lung UK, up to 9 in 10 children will contract RSV before they turn two years old and around 175,000 people over the age of 65 visit their GP about RSV each year. How does it spread? Dr Whittamore said: "Like most respiratory viruses, RSV spreads by people coughing and sneezing droplets from their own respiratory tract and it is spread to other people that way, It is often spread and caught in the air, by contact or if it ends up on surfaces." While RSV can circulate all year round, it typically peaks during the colder months. He said: "We see a major peak in cases in the NHS between October and February, particularly in December/January time." What are the most common symptoms? "As a GP, I see a lot of people with respiratory viruses and you can't really tell whether it's flu, Covid, RSV or the common cold," Dr Whittamore says. "Common symptoms are a runny nose, blocked nose, sneezing, coughing, feeling tired etc. People might also have a fever with it and if it's affecting their respiratory system itself, they might experience breathless or wheezing as well." A high temperature is also another key sign to look out for, according to the NHS website. Dr Whittamore said: "For most people, these symptoms tend to last no more than a week to 10 days." Can it lead to any serious complications? RSV can lead to some serious complications such as pneumonia or bronchiolitis for high-risk groups such as babies, young children and older people. Dr Whittamore said: "What we see with RSV, especially in younger children under the age of two, is that it can cause bronchiolitis, which causes quite dramatic breathing effects which can quite often put people in hospital. "We are also seeing that RSV is having a big impact on people over 75. We know that in that age group, the virus is more likely to cause them problems with their breathing and could go on and cause pneumonia and is likely to increase their chances of going to hospital." The NHS website also states that individuals with weakened immune systems, or long-term lung or heart conditions, and those who smoke tobacco are also at risk. A more serious infection (such as pneumonia or bronchiolitis) may cause a cough that gets worse, shortness of breath, noisy breathing (wheezing), faster breathing or long gaps between breaths, difficulty feeding in babies or loss of appetite, and confusion in older adults, according to the NHS website. How is it treated? RSV often improves on its own in one or two weeks, so you can usually manage it at home. Dr Whittamore said: "One important thing to do is to keep well hydrated, people with RSV should be pushing their fluids, resting more, taking paracetamol and can usually monitor themselves. However, if you are worried about yourself or your child, then seek advice from your GP or call 111." Can it be prevented? There are some measures you can take to reduce your chances of contracting RSV or spreading it to anyone else. Dr Whittamore said: "Make sure that when you are blowing your nose or sneezing that you use a tissue and throw it away, also, remember to wash your hands and clean surfaces regularly." The GP emphasises that the most crucial way to prevent people from falling ill with RSV is to ensure you receive the RSV vaccination if you are eligible for it. The RSV jab is recommended if you're expecting (from 28 weeks of pregnancy) – to help safeguard your baby for the first few months after they're born – or if you're aged between 75 and 79. Fresh research from the UK Health Security Agency (UKHSA) has revealed the RSV vaccine is around 82% effective in preventing older people being hospitalised with an RSV infection. "Most GP practices are contacting people and inviting them in, but if somebody thinks they're eligible and haven't been contacted they should contact their GP surgery and see if they can get it booked in," recommends Dr Whittamore.

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

Yahoo

time5 hours ago

  • Yahoo

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ('efti'), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating efti in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab), the FDA agreed on the potential of efti in combination with KEYTRUDA to address the high unmet need in this CPS <1 patient segment and is supportive of the combination's further development. Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data. 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,' said Marc Voigt, CEO of Immutep. 'Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer,' added Mr Voigt. Project FrontRunner is an FDA Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to develop and seek approval of cancer drugs for advanced/metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients' lives. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy's progress in fighting cancer, anti-PD-1 therapy alone (without chemotherapy) is only approved for patients who express PD-L1 (CPS >1). All currently available treatment options for patients with PD-L1 CPS <1 include chemotherapy. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Yahoo

time9 hours ago

  • Yahoo

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Launch complements existing Tweed and Spectrum Therapeutics product portfolio SMITHS FALLS, Ontario, August 05, 2025--(BUSINESS WIRE)--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. "Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options," said Andrew Bevan, SVP, Global Medical. "With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia." "Global medical is one of Canopy Growth's largest commercial opportunities," said Luc Mongeau, Chief Executive Officer. "Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform." The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. About Canopy GrowthCanopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ("Canopy USA"). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. For more information visit View source version on Contacts Alex ThomasDirector, Tyler BurnsDirector, Investor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store